HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

HC Wainwright & Co. has upgraded Crescent Biopharma (NASDAQ: CBIO) from a Neutral rating to a Buy rating. The firm has set a price target of $36 for the company's stock.